The company sources raw materials for consumable medication packages primarily from dual-sourced geographies. It engages contract manufacturers under agreements that define terms for quality, cost, delivery, manufacturing processes, supply continuity, inventory management, capacity flexibility, manufacturing oversight, and intellectual property use. Operations procure components and schedule production based on customer order backlog. Equipment and software installation timelines range from three weeks to 24 months, depending on complexity. Shipments of consumables typically occur within one to four weeks after order receipt.
Omnicell Inc's Comment on Supply Chain
The company sources raw materials for consumable medication packages primarily from dual-sourced geographies. It engages contract manufacturers under agreements that define terms for quality, cost, delivery, manufacturing processes, supply continuity, inventory management, capacity flexibility, manufacturing oversight, and intellectual property use. Operations procure components and schedule production based on customer order backlog. Equipment and software installation timelines range from three weeks to 24 months, depending on complexity. Shipments of consumables typically occur within one to four weeks after order receipt.
Sources:
Omnicell inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Omnicell inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
